The ECI1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from human A-549 lung adenocarcinoma cells, with targeted disruption of the ECI1 gene. This heterogeneous pool provides a loss-of-function model for studying mitochondrial enoyl-CoA delta isomerase in fatty acid metabolism. The polyclonal nature avoids clonal artifacts and ensures robust phenotypic analysis, enabling dissection of lipid oxidation pathways in cancer biology.
The A-549 line is a widely used model of non-small cell lung cancer, originally established from alveolar epithelial cells. These adherent cells are employed extensively in cancer metabolism, drug resistance, and signal transduction research. They retain alveolar type II characteristics, making them relevant for investigating lung adenocarcinoma biology and lipid handling. The ECI1 knockout in this background offers a physiologically appropriate system for studying how unsaturated fatty acid oxidation influences tumor cell energetics and survival.
ECI1 encodes mitochondrial enoyl-CoA delta isomerase, which catalyzes the isomerization of 3-cis-enoyl-CoA to 2-trans-enoyl-CoA, an essential step in ??-oxidation of unsaturated fatty acids. This enzyme acts downstream of PPAR-?? and PGC-1??, transcriptional regulators induced by AMPK signaling under energy stress. The isomerized product enters the mitochondrial trifunctional protein complex and is processed by very long-chain acyl-CoA dehydrogenase, enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase, and 3-ketoacyl-CoA thiolase. ECI1 disruption thus blocks unsaturated lipid degradation, reducing acetyl-CoA and ATP production and perturbing lipid homeostasis.
Lung adenocarcinoma cells often reprogram lipid metabolism to support growth. The ECI1 knockout in A-549 cells allows interrogation of their reliance on unsaturated fatty acid oxidation for energy and anabolism. By creating a metabolic bottleneck, this model reveals vulnerabilities in mitochondrial lipid catabolism. Comparative studies between knockout and wild-type populations under lipid-rich versus glucose-depleted conditions can uncover metabolic dependencies and potential therapeutic targets in non-small cell lung cancer.
Applications include fatty acid oxidation assays using radiolabeled oleate, metabolic flux analysis with 13C-labeled fatty acids, and gene expression profiling of ??-oxidation enzymes. Western blotting for oxidative phosphorylation complexes and cell viability assays under defined nutrient conditions complement these studies. This polyclonal knockout model enables detailed examination of unsaturated fatty acid metabolism in lung cancer, supporting drug sensitivity testing and metabolic vulnerability research. For inquiries, please contact Ascent Research.
